(च) अन्य कोई विनिर्माता विशेष विशेषताओं सहित गैर–काँच पैक के विशेष अधिकतम कीमत के लिए अलग से दावा करता है तो उसके लिए उसे विवरण के साथ प्रमाणित करना होगा कि उसके पैक में व्यापक सुविधाओं जैसे कि (i) स्वयं सिमटने और स्वयं सीलेबिलिटी (सील लगना) (ii) एयर वेंट नहीं होने और (iii) विनिर्माण के दौरान संचार/एडमिक्सिंग स्तरों पर संदूषण की संभावना नही हैं, के समर्थन में दस्तावेजों और प्रदर्शन सहित एनपीपीए को आवदेन करेगा।

(छ) विनिर्माता अपनी विनिर्मितियों की किसी भी अन्य विशेष विशेषताओं का दावा या अन्य पैक आकार के लिए विशेष मूल्य निर्धारण के लिए एनपीपीए में आवेदन करेगा।

(ज) औषध (मूल्य नियंत्रण) आदेश, 2013 के पैराग्राफ 11 में दिए गए प्रावधानों के तहत सम्बन्धित निर्माताओं को उपर्युक्त सारणी के स्तंभ (5) में विनिर्दिष्ट अधिकतम कीमत के आधार पर अनुसूचित विनिर्मितियों के पैकों के लिए अधिकतम कीमत निर्धारित करें। विनिर्माता औषध (मूल्य नियंत्रण) आदेश, 2013 के पैराग्राफ 24 के तहत फॉर्म V में अधिसूचना की तारीख से आईपीडीएमएस के माध्यम से भरकर एनपीपीए को एक मूल्य सूची जारी करेगा तथा उसकी कॉपी राज्य औषधि नियंत्रकों और विनिर्माता वितरक को जारी करेगा।

(झ) औषध (मूल्य नियंत्रण) आदेश, 2013 के पैरा 24 (4) के अनुसार प्रत्येक फुटकर विक्रेता और वितरक विनिर्माता द्वारा दिए गए रूप में ऐसे परिसर, जहां कारोबार को इस प्रकार किया जा रहा है कि उससे परामर्श के इच्छुक किसी व्यक्ति के लिए पहुंच आसान हो, वहां उसके किसी सहजदृश्य भाग पर कीमत सूची और पूरक सूची, यदि कोई हो, को संप्रदर्शित करेगा।

(ण) उपर्युक्त सारणी के स्तंभ (5) में विनिर्दिष्ट अधिकतम कीमत के लिए विनिर्दिष्ट अनुसूचित विनिर्मितियों के विनिर्दिष्ट विभिन्न तरीके और प्रबलता से भिन्न अगर मौजूदा निर्माताओं द्वारा एक नई औषधि लांच करता है तो उसे पहले औषध (मूल्य नियंत्रण) आदेश, 2013 के पैराग्राफ 2(u) के अनुसार औषध (मूल्य नियंत्रण) आदेश, 2013 के तहत सूची II में विनिर्दिष्ट फार्म I के माध्यम से एनपीपीए में मूल्य निर्धारण हेतु आवेदन करना होगा।

(त) उपर्युक्त अनुसूचित विनिर्मितियों के उत्पादन/आयात और बिक्री के सम्बन्ध में निर्माताओं को औषध (मूल्य नियंत्रण) आदेश, 2013 की सूची II के फॉर्म III को आईपीडीएमएस के माध्यम से भरकर एनपीपीए को हर तिमाही की रिपोर्ट प्रस्तुत करनी होगी। उपर्युक्त अनुसूचित विनिर्मितियों के विनिर्माण को कोई निर्माता उत्पादन बन्द करने का इच्छुक हो तो इसकी सूचना से एनपीपीए को अवगत करायेगा। इसके सम्बन्ध में अगर अनुसूचित विनिर्मितियों के उत्पादन और आयात को बन्द करने का इच्छुक है, तो बन्द करने की तिथि से छः महीने पहले सूची II के फॉर्म IV में भरकर एनपीपीए को प्रस्तुत करेगा।

(थ) विनिर्माता या विपणन कम्पनी, उपरोक्त कथित सारणी में दर्शाये अधिकतम मूल्य और नोट का पालन नहीं करती हैं तो वे आवश्यक वस्तुएँ अधिनियम, 1955 के साथ पठित डीपीसीओ, 2013 के प्रावधानों के अधीन ब्याज सहित अधिप्रभारित राशि को जमा करने के लिए उत्तरदायी होंगे।

(द) इस आदेश में उपरोक्त सारणी के स्तंभ (2) में की गई तत्स्थानी प्रविष्टि में विनिर्दिष्ट ऐसी विनिर्मितियों के पैकों की अधिकतम कीमत नियत होने के परिणामस्वरुप, अधिकतम या खुदरा मूल्य निर्धारित आदेश, यदि कोई हो, जो इस आदेश से पूर्व जारी हुए हैं, स्वतः ही अधिक्रमण हो जायेंगे।

[का. सं. /216/84/2021/एफ/फा. सं. 8(84)/2021/डीपी/एनपीपीए-डिवी-II]

प्रसेनजीत दास, उप निदेशक

ORDER

New Delhi, the 25th March, 2021

S.O. 1332(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. SO. 1215(E) dated 25.03.2020, SO. 2823(E) dated 20.08.2020, SO. 3320(E) dated 25.09.2020, S.O. 3974(E) dated 03.11.2020 and SO. 522(E) dated 04.02.2021, in so far as they relate to formulation packs of Non-Glass with special features (mentioned as Non-PVC in S.O. 1993(E) dated 3rd June 2016) mentioned in the Table A herein below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2020 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE-A

Price Revision as per Annual Wholesale Price Index (WPI) @ 0.53638% increase.

Sl. No.	Medicines	Dosage form and Strength	Unit	Ceiling price (wef 01.04.2021 with WPI @ 0.53638%)
(1)	(2)	(3)	(4)	(5)
1	Glucose	Injection 5%	1000ml Non Glass with special features	76.58
2	Glucose	Injection 5%	500ml Non Glass with special features	66.25
3	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	1000ml Non Glass with special features	80.47
4	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	500ml Non Glass with special features	68.86
5	Sodium Chloride	Injection 0.9%	100ml Non Glass with special features	33.86
6	Sodium Chloride	Injection 0.9%	250ml Non Glass with special features	50.01
7	Sodium Chloride	Injection 0.9%	500ml Non Glass with special features	70.81
8	Sodium Chloride	Injection 0.9%	1000ml Non Glass with special features	79.31

TABLE 'B'

Sl. No.	Name of Manufacturer	Product /Brand Name
(1)	(2)	(3)
1	M/s. B.Braun Medical (I) Pvt Ltd.	Ecoflac Plus bottle with Eurohead
2	M/s. Amanta Healthcare Ltd.	Steriport bottle
3	M/s. Aculife Healthcare Pvt Ltd.	Aculife bottle with Eurohead
4	M/s. Albert David Limited	Albert David bottle with Eurohead
5	M/s. Denis Chem Limited	Aquapulse with Eurohead
6	M/s. Claris Life Sciences Limited	Claris bottle with Eurohead
7	M/s. Fresenius Kabi India Pvt Limited	Freeflex bags
8	M/s. Otsuka Pharmaceutical India Private Ltd. (previously known as Claris Otsuka Private Limited)	Unibag
9	M/s. Aishwarya Lifesciences	Lifusion Eurohead bottle
10	M/s. Baxter (India) Pvt. Ltd.	Viaflex bags
11	M/s. Otsuka Pharmaceutical India Private Ltd. (previously known as Claris Otsuka Private Limited)	Eurohead bottle
12	M/s. Fresenius Kabi India Pvt Limited	Eurohead bottle
13	M/s. Axa Parenterals Ltd	Steri Drip bottle with Eurohead
14	M/s. Shree Krishna Keshav Laboratories Ltd	Easyport bottle with Eurohead
15	M/s. Rusoma Laboratories Pvt. Ltd.	Puradrip
16	M/s. R. K. Laboratories Pvt. Ltd.	Eurohead bottle
17	M/s. Eurolife Healthcare Pvt. Ltd.	Life port
18	M/s. Realcade Lifescience Pvt. Ltd.	Euro head bottle
19	M/s. Puniska Healthcare Pvt. Ltd [Note (b) below]	Non –PVC bag

Notes:-

(a) The ceiling prices are applicable with effect from 01.04.2021 (ceiling prices are inclusive of Wholesale Price Index (WPI) @0.53638% for the year 2020 over 2019).

(b) In case of M/s Puniska Healthcare Pvt. Ltd. only the prices of the formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable.

(c) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(d) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.53638% for year 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

(e) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(f) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack has all of the features as (i) self collapsibility and self-sealability (ii) not having air-vent; and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels alongwith documentation and demonstration.

(g) For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation

(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/216/84/2021/F/F. No. 8(84)/2021/DP/NPPA-Div.-II]

PRASENJIT DAS, Dy. Director